Industry: Pharmaceuticals, Biotechnology
GENETIC IMMUNITY, a US – Hungarian next generation bio- pharmaceutical company founded in 1998, has developed a patented immunotherapeutic platform technology which addresses unmet medical needs for chronic diseases. The lead product, DermaVir Patch, has successfully completed a Phase 1 clinical trial in Hungary demonstrating the product is safe and immunogenic in HIV-infected individuals. A Phase 2 trial in Sweden sponsored by the Karolinska Institute and an NIH sponsored Phase1/2 trial in the US both commenced in 2006 and are ongoing. The Company’s vaccine composition mimics the successful induction of antiviral immune responses via plasmid DNA expressing dendritic cells and the non-viral vaccine delivery enhances the activation of therapeutic T cell ( www.geneticimmunity.com )
Genetic Immunity Ltd.
8300 Greensboro Drive Suite 800
McLean, Virginia 22102
USA
Tel: (703) 883-0312